Abstract
Data from phase II and phase III clinical studies of the third-generation EGFR-TKI Aumolertinib showed significant treatment efficacy and a favorable safety profile for patients with EGFR-sensitive mutations (EGFRm+) in advanced non-small cell lung cancer (NSCLC). There is a difference in the incidence of AEs caused by osimertinib with the same 3rd generation EGFR-TKI, especially the low incidence of AEs caused by Aumolertinib in interstitial lung disease, cardiotoxicity, and hematotoxicity. The aim of this study was to evaluate the safety and efficacy of Aumolertinib in EGFRm+ advanced NSCLC patients with safety intolerance after treatment with oxitinib.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
